Skip to content
HowShorted

KALA BIO, Inc. short interest in 2021

In 2021, KALA BIO, Inc.'s disclosed short interest ran from 15.91% of shares outstanding on 15 Jan 2021 to 6.45% on 31 Dec 2021, a change of -9.46 percentage points. The year's high was 19.05% on 31 Mar 2021 and its low 6.45% on 31 Dec 2021, averaging 13.84% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.10 days on 30 Sep 2021. Full history: KALA BIO, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for KALA BIO, Inc. in 2021

2021 in figures

Start of year
15.91% (15 Jan 2021)
End of year
6.45% (31 Dec 2021)
Change
-9.46 pp
High
19.05% (31 Mar 2021)
Low
6.45% (31 Dec 2021)
Average
13.84%
Highest days to cover
10.10 (30 Sep 2021)
SEC filings marked
9

Every report in 2021

KALA BIO, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202115.91%4.91results (8-K)
29 Jan 202116.88%4.38
12 Feb 202116.65%4.24
26 Feb 202117.20%4.6210-K filed, results (8-K)
15 Mar 202118.04%6.62
31 Mar 202119.05%3.59
15 Apr 202116.21%9.63
30 Apr 202115.69%7.40
14 May 202112.62%2.2710-Q filed, results (8-K)
28 May 202112.06%4.01
15 Jun 202112.46%3.12
30 Jun 202113.19%4.53
15 Jul 202113.08%3.79
30 Jul 202113.79%6.23
13 Aug 202113.09%5.4110-Q filed, results (8-K)
31 Aug 202114.91%9.58
15 Sep 202112.56%8.29
30 Sep 202114.13%10.10
15 Oct 202113.54%8.52
29 Oct 202113.09%3.60
15 Nov 202112.94%4.5710-Q filed, results (8-K)
30 Nov 202110.85%4.50
15 Dec 20217.87%5.06
31 Dec 20216.45%3.09

See also: KALA BIO, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.